MA26681A1 - Composes pyrazine - Google Patents

Composes pyrazine

Info

Publication number
MA26681A1
MA26681A1 MA25746A MA25746A MA26681A1 MA 26681 A1 MA26681 A1 MA 26681A1 MA 25746 A MA25746 A MA 25746A MA 25746 A MA25746 A MA 25746A MA 26681 A1 MA26681 A1 MA 26681A1
Authority
MA
Morocco
Prior art keywords
pyrazine compounds
pyrazine
compounds
Prior art date
Application number
MA25746A
Other languages
English (en)
Inventor
Cox Brian
Wild Deborah
Patrick Healy Mark
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26681A1 publication Critical patent/MA26681A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25746A 1998-08-28 1999-08-27 Composes pyrazine MA26681A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9818881.6A GB9818881D0 (en) 1998-08-28 1998-08-28 Compounds

Publications (1)

Publication Number Publication Date
MA26681A1 true MA26681A1 (fr) 2004-12-20

Family

ID=10838055

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25746A MA26681A1 (fr) 1998-08-28 1999-08-27 Composes pyrazine

Country Status (15)

Country Link
US (2) US6503909B1 (fr)
EP (1) EP1107960A1 (fr)
JP (1) JP2002523499A (fr)
KR (1) KR20010079696A (fr)
CN (1) CN1324349A (fr)
AU (1) AU5624999A (fr)
BR (1) BR9913183A (fr)
CA (1) CA2341543A1 (fr)
CO (1) CO5130006A1 (fr)
GB (1) GB9818881D0 (fr)
MA (1) MA26681A1 (fr)
PE (1) PE20001022A1 (fr)
TR (1) TR200100603T2 (fr)
TW (1) TW429255B (fr)
WO (1) WO2000012488A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500653A1 (fr) * 2000-02-16 2005-01-26 Neurogen Corporation Arylpyrazines substituées
PL365238A1 (en) 2000-02-16 2004-12-27 Neurogen Corporation Substituted arylpyrazines
GB0010971D0 (en) 2000-05-05 2000-06-28 Glaxo Group Ltd Process
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1501514B1 (fr) * 2002-05-03 2012-12-19 Exelixis, Inc. Modulateurs de proteine-kinases et leurs methodes d'utilisation
EP1554258A1 (fr) 2002-08-20 2005-07-20 Neurogen Corporation 2-arylpyrazines substituees en 5 comme modulateurs sur les recepteurs crf
CA2529623A1 (fr) * 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
JPWO2005095613A1 (ja) * 2004-03-30 2008-02-21 ジェノミディア株式会社 Rad51の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2423226A3 (fr) * 2006-11-10 2012-05-30 Amgen Inc. Diagnostic à base d'anticorps et thérapeutique
EP2460828A3 (fr) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Anticorps et diagnostic
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
CN118891255A (zh) * 2022-03-16 2024-11-01 阿鲁姆治疗公司 新化合物及其抑制检查点激酶2的用途
CN115611700B (zh) * 2022-10-11 2024-06-14 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575975A (en) * 1968-07-25 1971-04-20 Merck & Co Inc Process for the preparation of 3-aminopyrazinoylureas
US3544568A (en) * 1969-03-18 1970-12-01 Merck & Co Inc 3-amino-5,6-substituted pyrazinamides
US4402958A (en) 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.

Also Published As

Publication number Publication date
GB9818881D0 (en) 1998-10-21
CO5130006A1 (es) 2002-02-27
JP2002523499A (ja) 2002-07-30
KR20010079696A (ko) 2001-08-22
PE20001022A1 (es) 2000-10-16
TR200100603T2 (tr) 2001-07-23
CA2341543A1 (fr) 2000-03-09
US6503909B1 (en) 2003-01-07
AU5624999A (en) 2000-03-21
BR9913183A (pt) 2001-05-15
EP1107960A1 (fr) 2001-06-20
WO2000012488A1 (fr) 2000-03-09
US20030022904A1 (en) 2003-01-30
CN1324349A (zh) 2001-11-28
TW429255B (en) 2001-04-11

Similar Documents

Publication Publication Date Title
DE69818643T2 (de) Pyrazin-Verbindungen
FR09C0030I2 (fr) Composes thrombopoietiques
ATE229954T1 (de) Betacarbolinverbindungen
ID28266A (id) Senyawa-senyawa amidin
NO20011745L (no) Forbindelser
EP1076337A4 (fr) Enregistreur-lecteur
ID23761A (id) Trisiklik tersubstitusi
NO20005006L (no) Kalsilytiske forbindelser
EP1087957A4 (fr) Composes auto-inducteurs
MA26681A1 (fr) Composes pyrazine
ID23219A (id) Trisiklik tersubstitusi
NO20006662D0 (no) Fluorfenylresin-forbindelser
MA26587A1 (fr) Composes de triazine
DE69913027D1 (de) Verdampfer
DE69938388D1 (de) Empfänger
FI980044A0 (fi) Foerfarande foer behandling av en fiberbana
DE59911610D1 (de) Substituierte benzoylcyclohexandione
EP1105133A4 (fr) Composes tricycliques
DE59912532D1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
NO980270D0 (no) Trekkanordning
ATA32198A (de) Beschlag
DE69838138D1 (de) Empfänger
FR2782553B1 (fr) Evaporateur
FI980095A0 (fi) Foerfarande foer byggande av fartyg